A Phase 4 interventional study of Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) and Travoprost 0.004% eye drops in Open-angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-12.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 25th largest by enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2007, is one of 22 in phase 4, and was the 11th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Jonathon Myers · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 135 across the 45 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 71st largest by enrollment of the 112 interventional ones that give a count, is one of 9 that started in 2007, is one of 31 in phase 4, and was the 31st registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare adherence in patients on a fixed combination of travoprost 0.004%/timolol 0.5% and patients on a concomitant combination of travoprost 0.004% and timolol 0.5% using the Travalert® device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
Drug: Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) · Device: Travalert Dosing Aid
One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.
Drug: Travoprost 0.004% eye drops · Drug: Timolol 0.05% eye drops · Device: Travalert Dosing Aid
Drug page: Travoprost
One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
Also known as: DuoTrav®
One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
Approved device used with study medication to record time of instillation and quantify dosing
Adherence
Patients were considered adherent if a minimum of 80% of their instillations were administered ±2 hours of the scheduled time.
Time frame: 6 months
Patients were recruited from 5 hospitals in Spain.
| Milestone | Travalert With Travoprost/Timolol Fixed Combination | Travalert With Travoprost and Timolol |
|---|---|---|
| Started | 52 | 50 |
| Completed | 35 | 40 |
| Not completed | 17 | 10 |
Patients were considered adherent if a minimum of 80% of their instillations were administered ±2 hours of the scheduled time.
| percentage of adherent patients | Travalert With Travoprost/Timolol Fixed Combination | Travalert With Travoprost and Timolol |
|---|---|---|
| Adherence | 63 | 43 |
Collected over Adverse events were collected for the duration of the study: 2 years, 3 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Travalert With Travoprost/Timolol Fixed Combination | — | 1/52 (1.9%) | 0/52 (0%) |
| Travalert With Travoprost and Timolol | — | 1/50 (2%) | 0/50 (0%) |
| Event | Travalert With Travoprost/Timolol Fixed Combination | Travalert With Travoprost and Timolol |
|---|---|---|
| BrachycardiaCardiac disorders | 0/52 | 1/50 |
| Heart FailureCardiac disorders | 1/52 | 0/50 |
| Age Continuous(years) | Travalert With Travoprost/Timolol Fixed Combination | Travalert With Travoprost and Timolol | Total |
|---|---|---|---|
| Mean | 63.8 ± 11.1 | 68.6 ± 11.8 | 66.2 ± 11.6 |
| Sex: Female, Male(Participants) | Travalert With Travoprost/Timolol Fixed Combination | Travalert With Travoprost and Timolol | Total |
|---|---|---|---|
| Female | 26 | 25 | 51 |
| Male | 17 | 17 | 34 |
The record gives a start of Oct 2007, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Travoprost · Timolol